Your Health, We Care

Home > Photo Wall > Honor and qualification

Production approval for brigatinib180mg

Release date: 2024-07-09 15:25:00     Recommended: 77

02L1066_24 布加替尼180mg 批文_00.jpg

Bugatinib monotherapy is suitable for specific lung diseases. Bugatinib is an ALK tyrosine kinase inhibitor that can inhibit the proliferation of malignant cells, promote disease recovery, and alleviate discomfort symptoms. Its therapeutic effect has been validated through long-term clinical trials and studies.

Company News

Research News

Drug news